Pralidot 1000 mg/ml
Pralidoxime Chloride
Category: IV Injection
Manufacturer: Globe Pharmaceuticals Ltd.
Allopathic
MFG. Licence No. Biological
182
MFG. Licence No. Non-Biological
50
Address
Begumganj, Noakhali.
Price: 500.0 ৳
1 ml vial
Medicine Selling service is not available yet.
Uses of Pralidot:
- Organophosphate poisoning
Organophosphorous poisoning, Overdoses of anticholinesterase drugs used in the treatment of, myasthenia gravis.
Carbamate pesticide poisoning, hypersensitivity.
Antidote preparations
Pralidoxime reactivates cholinesterase outside the CNS that had been inactivated by phosphorylation due to exposure to certain organophosphates by displacing the enzyme from its receptor sites. It removes the phosphoryl group from the active site of the inactivated enzyme by nucleophilic attack, regenerating active cholinesterase and forming an oxime complex. It also detoxifies certain organophosphates by direct chemical reaction.
How to use
Pralidoxime Chloride:
Your doctor or nurse will give you this medicine. Kindly do not self administer.
Administration:
IV Preparation
Reconstitute by adding 20 mL SWI to the 1 g vial to provide a 50 mg/mL solution (do not use preservative-containing solutions)
IV Administration
For infusion, dilute required amount of reconstituted solution to 100 mL with NS
Infuse over 15-30 min
May also be given as 5 min slow IVP
IM Administration
1 g vial contents may be reconstituted by adding 3 mL SWI or NS to provide a 300 mg/mL solution
Adult Dose:
Organophosphorous Poisoning
For IV Infusion:
Adults: 1-2 g IV as 15-30 min infusion, repeat a second dose of 1 g to 2 g may be indicated after about one hour if muscle weakness has not been relieved. Additional doses may be given every 10-12 hours if muscle weakness persists.
OR
Use with atropine, which affects muscarinic receptors; pralidoxime's actions most striking at nicotonic sites (increase muscle strength 10-40 min)
For IV Injection: For fluid restricted patient 1 g, should be slowly given (over not less than 5 minutes) by IV injection, as 50 mg/ml solution in normal saline (e.g. 1 g in 20 ml).
IM: 600 mg IM x3 doses; administer each dose 15 minutes apart for mild symptoms, or in rapid succession for severe symptoms
Acetylcholinesterase Inhibitor Toxicity
Initial: 30 mg/kg IV (IM, SC if no IV access) over 20 min
4-8 mg/kg/hr IV infusion
Child Dose:
Organophosphorous Poisoning
For IV Infusion:
Children > 16 years of age: 1-2 g IV as 15-30 min infusion, repeat a second dose of 1 g to 2 g may be indicated after about one hour if muscle weakness has not been relieved. Additional doses may be given every 10-12 hours if muscle weakness persists.
OR
Use with atropine, which affects muscarinic receptors; pralidoxime's actions most striking at nicotonic sites (increase muscle strength 10-40 min)
For IV Injection: For fluid restricted patient 1 g, should be slowly given (over not less than 5 minutes) by IV injection, as 50 mg/ml solution in normal saline (e.g. 1 g in 20 ml).
Children < 16 years of age: Loading dose: 20-50 mg/kg (maximum: 2000 mg/dose); Maintenance infusion: 10-20 mg/kg/hour; alternatively, a repeat bolus of 20-50 mg/kg (maximum 2000 mg/dose) may be administered after 1 hour and repeated every 10-12 hours thereafter, as needed.
IM administration
<40 kg: 15 mg/kg/dose IM x3 doses
40 kg or greater: Administer as in adults; 600 mg/dose IM x3 doses
Renal Dose:
Renal Impairment: Reduce dose
Carbamate pesticide poisoning, hypersensitivity.
Common
- Accomodation disorder
- Dizziness
- Double vision
- Drowsiness
- Headache
- High blood pressure
- Increased heart rate
- Muscle weakness
- Nausea
Drowsiness, dizziness, visual disturbances, nausea, tachycardia, headache, hyperventilation and muscle weakness.
Potentially Fatal: Rapid admin causes tachycardia, laryngospasm and rigidity. Large doses cause neuromuscular blockade.
Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Precaution:
The following precautions should be kept in mind in the treatment of acetylcholinesterase poisoning, although they do not bear directly on the use of Pralidoxime Chloride, since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsion; morphine, theophylline, aminophylline, succinylcholine, reserpine and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. Prolonged paralysis has been reported with patients when succinylcholine is given with drugs having anticholinesterase activity; therefore it should be used with cautions. Pregnancy, lactation.
Manifestations of Overdosage: Observed in normal subjects only: dizziness, blurred vision, diplopia, headache, impaired accommodation, nausea, slight tachycardia. In therapy it has been difficult to differentiate side effects due to the drug from those due to the effects of the poison.
Store between 20-25° C.
Antidote preparations
Pralidoxime reactivates cholinesterase outside the CNS which has been inactivated by phosphorylation due to organophosphate pesticide exposure-resulting. This leads to the destruction of acetylcholine at the neuromuscular junction thus relieving muscle paralysis. It also removes the phosphyl group from the active site of inactivated enzyme which is dependent on the nature of the phosphyl group.
Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Samm Care